xCures hosts xDECIDE webinars

xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE.  Oncology providers now have access to a toolkit that offers tailored recommendations for treatment options and personalized patient health summaries.  To accompany the launch of the platform, Dr. Juneja discusses… Read more »

Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures

First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use. The Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) and partners announce the treatment of the first cancer patient with a personalized neoantigen vaccine through a self-pay compassionate use program. JLF is a 501(c)3 non-profit organization whose… Read more »

xCures Partners With Massive Bio to Help Advanced Cancer Patients Find the Right Treatment Options

Collaboration between leading AI-enabled oncology corporations helps provide the best arsenal available for advanced cancer patients NEW YORK–(BUSINESS WIRE)–Today, xCures announced their collaboration with Massive Bio Inc. This partnership ensures that advanced cancer patients and their physicians have access to the best treatment options available. Massive Bio is a leader… Read more »

xCures provides early access to xINFORM

Today, xCures enabled early access to xINFORM, an A.I.-powered platform for advanced cancer patients to identify personalized treatment options to discuss with their doctors. xINFORM is available at no charge. Patients participate with their data and receive treatment options that combine the leading thinking in precision medicine, patient preferences, and… Read more »